company background image
AX9 logo

Akebia Therapeutics DB:AX9 Stock Report

Last Price

€1.77

Market Cap

€383.7m

7D

4.2%

1Y

64.0%

Updated

23 Dec, 2024

Data

Company Financials +

Akebia Therapeutics, Inc.

DB:AX9 Stock Report

Market Cap: €383.7m

My Notes

Capture your thoughts, links and company narrative

Akebia Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Akebia Therapeutics
Historical stock prices
Current Share PriceUS$1.77
52 Week HighUS$2.85
52 Week LowUS$0.78
Beta0.70
1 Month Change4.12%
3 Month Change56.86%
1 Year Change63.98%
3 Year Change-18.01%
5 Year Change-69.20%
Change since IPO-87.77%

Recent News & Updates

Recent updates

Shareholder Returns

AX9DE BiotechsDE Market
7D4.2%-3.5%-2.0%
1Y64.0%-14.7%6.9%

Return vs Industry: AX9 exceeded the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: AX9 exceeded the German Market which returned 6.9% over the past year.

Price Volatility

Is AX9's price volatile compared to industry and market?
AX9 volatility
AX9 Average Weekly Movement8.5%
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: AX9's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: AX9's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2007167John Butlerwww.akebia.com

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.

Akebia Therapeutics, Inc. Fundamentals Summary

How do Akebia Therapeutics's earnings and revenue compare to its market cap?
AX9 fundamental statistics
Market cap€383.66m
Earnings (TTM)-€44.19m
Revenue (TTM)€163.24m

2.4x

P/S Ratio

-8.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AX9 income statement (TTM)
RevenueUS$169.88m
Cost of RevenueUS$26.95m
Gross ProfitUS$142.93m
Other ExpensesUS$188.92m
Earnings-US$45.99m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.21
Gross Margin84.13%
Net Profit Margin-27.07%
Debt/Equity Ratio-184.5%

How did AX9 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:12
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Akebia Therapeutics, Inc. is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Jonathan AschoffBrean Capital
Jonathan AschoffB. Riley Wealth